Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — 1H FY26 Earnings Presentation
12 slides from Lumos Diagnostics's earnings presentation, Mar 3, 2026
Slide 1: 1H FY26 Results - Investor Briefing Invitation
ASX ANNOUNCEMENT 1H FY26 Results - Investor Briefing Invitation MELBOURNE, Australia (3 March 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the For personal use only “Company”) a leader in rapid, point-of-care diagnostic technologies, has today released an investor presentation relatin
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements, including references to forecasts. Forward- looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are be
Slide 3: 1H FY26 Results Presentation
For personal use only Lumos Diagnostics Holdings Limited 1H FY26 Results Presentation 3 March 2026 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of (Company). achiev
Slide 5: Lumos develops, manufactures and distributes innovative diagnostic products
For personal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. © Lumos Diagnostics , all rights reserved 3
Slide 6: Lumos Business Overview
Lumos Business Overview For personal use only COMMERCIAL SERVICES PRODUCTS Development Contract manufacturing FebriDx® Women’s Health People and Capability drive value - able to leverage R&D, IP, manufacturing scale, medical, quality and regulatory skillset across Lumos’ Products and Commercial Serv
Slide 7: Pivotal Milestones Achieved in 1H FY26
Pivotal Milestones Achieved in 1H FY26 Securing pivotal U.S. exclusive distribution agreement with PHASE Scientific for For personal use only US$317m for FebriDx®. Completion of FebriDx® CLIA waiver clinical study and submission to U.S. FDA. Positive operating cash flow of $0.8m - Achieved 100% Medi
Slide 8: Financial Summary – Half Year
Financial Summary – Half Year Revenue ($M) Gross Profit ($M) & Margin For personal use only 7.0 $6.3 4.5 $4.2 $4.2 100% $6.1 6.0 4.0 3.5 80% 5.0 3.0 4.0 55% 67% 68% 60% 2.5 $2.8 2.0 3.0 $1.5 40% 1.5 2.0 1.0 20% 1.0 0.5 0.0 0.0 0% 1H FY24 1H FY25 1H FY26 1H FY24 1H FY25 1H FY26 Commentary Commentary
Slide 9: Financial Summary – Half Year
Financial Summary – Half Year Adjusted EBITDA* ($M) Net Cashflow Generation ($M)* For personal use only 0.0 1.0 $0.1 1H FY24 1H FY25 1H FY26 -0.5 0.0 -1.0 1H FY24 1H FY25 1H FY26 -1.0 -$0.9 -2.0 -1.5 -$1.4 -3.0 -2.0 -4.0 -2.5 -5.0 -3.0 -6.0 -$5.5 -3.5 -7.0 -$6.8 -4.0 -8.0 -4.5 -$4.2 Commentary Comme
Slide 10: Key Priorities
For personal use only Key Priorities FDA decision on the CLIA Implement agreement with Progress FebriDx paediatric Deliver on Hologic fFN Progress to formal product waiver for FebriDx® is PHASE Scientific, advance study – fully funded with development milestones - development on the first expected b
Slide 11: Investor Takeaways
Investor Takeaways For personal use only $ First in Class Product FebriDx® Nearing Major Transformational US$317M (A$487M) Underlying Financials Performance Improving US Breakthrough Distribution Deal • 1H FY26 revenue of $6.1M. • CLIA waiver study exceeded performance targets • With PHASE Scientifi
Slide 12: Investor Briefing Thank You
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing Thank You www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 10
Lumos Diagnostics Holdings — 1H FY26 Earnings Presentation on 6ix